Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
Date:3/5/2012

SAN DIEGO, March 5, 2012 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2011 financial results on Monday, March 12, 2012.

Cadence management will host a conference call and live webcast to discuss the financial results on Monday, March 12, 2012 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Interested investors may participate in the conference call by dialing (877) 303-9145 (domestic) or (760) 536-5203 (international).  To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investor Relations page.  A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting.  For more information about Cadence, please visit www.cadencepharm.com.

 Contacts:

William R. LaRue 

SVP & Chief Financial Officer 

Cadence Pharmaceuticals, Inc. 

858-436-1400


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2011 Financial Results on August 3, 2011
3. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
4. Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
5. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
7. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
8. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
9. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
11. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2015)... ... ... The global failure analysis market is expected to reach $7,147.0 million by 2020, ... to grow at the highest CAGR of 8.46%; its growth is expected to be ... academic institutions for root cause analysis of failure. The market based on the geographic ...
(Date:7/3/2015)... , July 3, 2015 ... 22. september 2015 på  http://www.openinnovationinscience.at om ... der finder sted i Wien ... undersøgelse af internationale forskere og videnskabsmænd foretaget ... to største udfordringer for sundhedsvidenskaben manglen på ...
(Date:7/2/2015)... , July 2, 2015 ... Bio-tech procurement company Amici Procurement has chosen Microsoft ... help it move to Office 365.      ... provides small to medium-sized companies in the bio-tech sector ... aspects of the purchasing cycle to help them obtain ...
(Date:7/1/2015)... and PARIS , ... AgBiome, and Genective, key developer of biotech crops, ... discovery of new generations of insect control traits. ... control to counter the realities of advancing insect ... aligning AgBiome,s unique insect control technology with Genective,s ...
Breaking Biology Technology:Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 2Lancering af verdens første åbne innovationsprogram til uddannelse af forskere 3Biotech Procurement Company Moves to Office 365 with iomart 2AgBiome and Genective collaborate to create novel insect-resistant crops 2
... June 19 Canopus,BioPharma, Inc. (OTC: CBIA), has ... a tumor reducing agent and has also demonstrated ... both cisplatin and,cetuximab (Erbitux) in two mice lung ... Patrick Prendergast, stated, "We at,Canopus are encouraged with ...
... Neuftec,Limited, the proprietor of the original nano-particulate cerium ... against Oxonica Energy,Limited, a wholly owned subsidiary of ... the High Court of Justice, has commented on ... Dr Matthews,(CEO) on 19 June 2008., Dr ...
... features Asian biopharmaceutical industry information on ... ... 19 BioSpace, the world,s,leading online community for the bioscience ... pharmaceutical and,medical devices industries in Asia. AsiaBio(TM) features dynamic,informational Hotbed ...
Cached Biology Technology:CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux). 2Neuftec Responds to a Fundamental Inaccuracy in Oxonica PLC's Regulatory Announcement 2BioSpace Announces New Online Community for Asia 2
(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
(Date:6/23/2015)... N.C. , June 23, 2015   ... today announced the results of a recent study ... accuracy on the wrist during activity. In a ... technology was compared along with the Apple Watch ... accurately measuring heart rate during activity. The study ...
(Date:6/18/2015)... , June 18, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market announces that ... featured segment on "Money on the Mark", scheduled to air ... June 20 th . The ... be from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO ...
Breaking Biology News(10 mins):KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3
... identified a key gene mutation responsible for type 2 diabetes ... The study, which originated in Italy and was validated ... to a major drop in the body,s ability to make ... the cell to absorb sugar. This drop in insulin receptors ...
... The American Heart Association estimates 35 percent of adults in ... factors characterized by obesity and the simultaneous presence of heart ... lipids. In patients with metabolic syndrome, high blood pressure ... affects the organ,s ability to filter waste from the body. ...
... able to navigate to specific locations up to 50km away, ... Journal of Animal Ecology has found. Re-analysing tracking data ... as blacktip reef sharks swim in a pattern known as ... times hunt for prey or mates by using "directed walks", ...
Cached Biology News:Type 2 diabetes linked to single gene mutation in 1 in 10 patients 2Study shows pine bark naturally improves kidney function in patients with metabolic syndrome 2Study shows pine bark naturally improves kidney function in patients with metabolic syndrome 3Shark tracking reveals impressive feats of navigation 2
Taq DNA Polymerase (cloned), 250 units. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Polymerases....
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
...
...
Biology Products: